Organon and
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Organon and sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Organon and: 15 sponsored US clinical trials, 1 recruiting.
Organon and sponsors 15 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 12 completed. 12 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis, with 4 trials.
Top-decile sponsor footprint
Organon and ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
NCT07265479
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
NCT05789576
A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis
NCT05680740
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
NCT05560646
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
NCT05264506
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
NCT05186805
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
NCT05142774
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
NCT05032859
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
NCT05014568
A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)
NCT04626596
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
NCT04053387
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
NCT04042103
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
NCT03983980
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
NCT03956355
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 10 |
| Phase 4 | 2 |
Therapeutic Areas
Where Organon and enrollment is open (later-stage tilt)
1 recruiting of 15 indexed (7% open); 12 completed (80%).
Phase mix: 12 late (III/IV) vs 3 early (I/II) (later-stage heavy).
Top condition: Atopic Dermatitis (4 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Organon and: open-pipeline peers nationwide
Peers matched on 15 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Organon and sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Baylor Breast Care Center · 7% recruiting · 15 trials
- Geron Corporation · 7% recruiting · 15 trials
- Guerbet · 7% recruiting · 15 trials
- Joanne Kurtzberg, MD · 7% recruiting · 15 trials
Related
What to do with this Organon and page
15 registered trials is a research-attention snapshot, not an endorsement of Organon and or any single study.
- 1 of Organon and's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atopic Dermatitis is the condition Organon and studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Organon and pipeline card: 15 registered trials from official public datasets.Report a data error.